Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
This cell line is a suitable transfection host.
This line has a mutation in codon 12 of the ras proto-oncogene, and can be used as a positive control for PCR assays of mutation in this codon.
A cell line established from a lymph node metastasis taken from the same patient one year later is available (see ATCC CCL-227).
The line is negative for CSAp (CSAp-) and colon antigen 3.
The cells are positive for keratin by immunoperoxidase staining.
There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution and a C -> T mutation in codon 309 resulting in a Pro -> Ser substitution.
The cells express elevated levels of p53 protein.
The line is positive for expression of c-myc, K-ras, H-ras, N-ras, myb, sis and fos oncogenes.
N-myc oncogene expression was not detected.
Matrilysin, a metalloproteinase associated with tumor invasiveness, is not expressed.
The cells have been reported to produce GM-CSF.
(Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation)
Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 77210034
Lelbovitz A, et al. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination. J. Natl. Cancer Inst. 63: 635-645, 1979. PubMed: 288927
Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832
Schroy PC, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 76: 201-209, 1995. PubMed: 8625092
Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874
Weiss J, et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer 54: 693-699, 1993. PubMed: 8514460
Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, 1989. PubMed: 2531845
Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498
Leibovitz A, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569, 1976. PubMed: 1000501
Geiser AG, et al. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49: 1572-1577, 1989. PubMed: 2647289
Lahm H, et al. Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. Cancer Res. 54: 3700-3702, 1994. PubMed: 8033086
Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228
Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479
Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066
Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224
Witty JP, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 54: 4805-4812, 1994. PubMed: 8062282
